Impact of the KEYNOTE-045 Study Comparing Pembrolizumab and Chemotherapy in Bladder Cancer

T-DM1 was tolerable in HER2-positive biliary tract adenocarcinoma but did not significantly improve progression-free survival.

Bevacizumab's survival benefits in CRC patients persist for about 2 years after starting treatment.

Patients with BRAF V600E-mutant metastatic colorectal cancer experienced poor clinical outcomes with systemic therapy, according to real-world data.

A "watch and wait" strategy after total neoadjuvant therapy showed similar outcomes and safety to total mesorectal in stage II/III rectal cancer.

Early palliative care reduces invasive interventions and enhances comfort at EOL for CRC patients, according to real-world study results.

Oral paclitaxel matched IV in progression-free survival but outperformed it in overall survival for second-line advanced gastric cancer.